A Conversation With FDA Interventional Cardiology Reviewer Andrew Farb
This article was originally published in The Gray Sheet
Executive Summary
When FDA needed experts to guide its response to the emerging drug-eluting stent thrombosis issue in 2006, it was lucky to find it already had a cardiovascular pathologist experienced with implantable devices on its review staff